| Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy (NCT02123511) | Mayo Clinic | 2014-04-01 |
| Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy (NCT01728480) | Roswell Park Cancer Institute | 2014-01-01 |
| Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy (NCT01674374) | Roswell Park Cancer Institute | 2013-05-01 |
| Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer (NCT01528137) | Stanford University | 2012-05-01 |
| TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck (NCT01334177) | University of Washington | 2011-06-01 |
| Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer (NCT01254734) | City of Hope Medical Center | 2011-04-01 |
| L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer (NCT01155609) | University of Washington | 2010-09-01 |
| Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy (NCT01682031) | Roswell Park Cancer Institute | 2009-06-01 |
| Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy (NCT00895245) | University of Washington | 2009-02-01 |
| Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC) (NCT00896181) | Stanford University | 2008-12-10 |
| Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck (NCT00906360) | National Cancer Institute (NCI) | 2008-07-01 |
| Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. (NCT01469429) | Ohio State University Comprehensive Cancer Center | 2007-09-04 |
| Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT00513435) | National Cancer Institute (NCI) | 2007-07-01 |
| Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer (NCT00492089) | National Cancer Institute (NCI) | 2007-06-01 |
| Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer (NCT00410826) | University of Washington | 2006-06-01 |
| Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer (NCT00101348) | National Cancer Institute (NCI) | 2005-01-01 |
| Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors (NCT00089362) | National Cancer Institute (NCI) | 2004-07-01 |
| Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and Neck (NCT00081211) | National Cancer Institute (NCI) | 2004-04-01 |
| Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck (NCT00063895) | National Cancer Institute (NCI) | 2003-04-01 |
| Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer (NCT00055770) | National Cancer Institute (NCI) | 2002-10-01 |
| Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer (NCT00049283) | National Cancer Institute (NCI) | 2002-09-01 |
| Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer (NCT00023959) | National Cancer Institute (NCI) | 2001-07-01 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (NCT00004074) | National Cancer Institute (NCI) | 1999-08-01 |